Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movymia

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

Sanofi reception

Sanofi licenses cardiovascular therapy in South Korea

Phase III drug comes from Swedish company NeuroVive

Sanofi appoints Suresh Kumar as EVP of external affairs

He previously worked for the Clinton Foundation focused on Sub-Saharan Africa

EU flag

Three cancer immunotherapies amongst new CHMP approvals

BMS’ Evotaz also amongst eight new medicine recommendations

- PMLiVE

EMA prepares to launch medical literature monitoring service

Will screen documents for 400 active substance groups

Sanofi reception

Sanofi says sarilumab filing for arthritis on track

Looks likely to be filed before the end of the year

- PMLiVE

Flurry of FDA guidance firms up biosimilar policy

The American regulator has released new biosimilar Q&A document

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

EU flag

EMA to stop ‘revolving doors’ committee members

Comes nearly five years after its former director left for a pharma service firm

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links